Furthermore, FGF21 treatment prevents cardiac hypertrophy development (at least, in neonatal mouse models), enhances fatty acid oxidation, and prevents the induction of pro-inflammatory pathways in the heart, thereby confirming the anti-hypertrophic properties of FGF21 (13). The gene discussed is FGF21; the disease is cardiac hypertrophy.